Vaxess Technologies

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Vaxess is a preclinical company developing a pipeline of novel immunooncology therapeutics and vaccines on the MIMIX Smart Release platform. MIMIX combines lymph node targeting with local dermal delivery, tunable release kinetics, and powerful T cell activation to enable next generation oncology therapies. Vaxess's lead program is targeting melanoma with follow-on programs aimed at additional skin carcinomas. The company has deep expertise in immune activation, with a broadly protective influenza vaccine also preparing for clinical entry.

The company is headquartered in Boston and combines novel technologies from Tufts and MIT. The company has raised more than $20M in equity financing and grants from leading VC's as well as the NIH, NSF, and DARPA amongst others.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
MIMIX-Melanoma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Vaxess Technologies, Inc.